Daewoong Pharmaceutical jumped more than 9% in early trading on the 3rd. Buying appears to be pouring in after Daewoong Pharmaceutical said that its gastroesophageal reflux disease (GERD) treatment "Fexuclu" (fexuprazan hydrochloride) showed symptom improvement after it went on the market.
At 9:21 a.m., Daewoong Pharmaceutical was trading at 136,300 won on the Korea Exchange, up 11,800 won (9.48%) from the previous session. It climbed as high as 142,100 won at one point in early trading.
Daewoong Pharmaceutical said the interim analysis of Fexuclu confirmed symptom improvement in 95.75% of all patients, including those age 65 and older. The findings were published in the SCIE-tier international journal in gastroenterology, "Gut and Liver."
A post-marketing study is research that verifies safety and efficacy in the process of actual clinical use after a drug is approved. This interim analysis was conducted based on real-world data (RWD) of a certain scale accumulated before the entire study is completed.
Park Hyeong-cheol, head of ETC Marketing at Daewoong Pharmaceutical, said, "This analysis shows that Fexuclu demonstrates strong efficacy and high safety even in a complex real-world prescribing environment," adding, "We will continue to build robust medical evidence through ongoing research and further strengthen product competitiveness."